

**Cancer Cachexia: Molecular Mechanisms and Therapeutic Approaches**  
Boston, September 21-23, 2012

**Friday, September 21, 2012**

1:00 pm	Registration and Poster Set-up	<b>Belvidere Foyer</b> <b>Maverick A&amp;B</b>
4:00-4:10 pm	<b>Introductory Remarks</b> Denis Guttridge, PhD Professor, Molecular Virology, Immunology and Medical Genetics The Ohio State University Columbus, Ohio	<b>Adams A&amp;B</b>
4:10-5:10 pm	<b>(Keynote Address) - Mechanisms of muscle atrophy and hypertrophy</b> David Glass, PhD Global Head, Musculoskeletal Diseases Group Novartis Institutes for Biomedical Research Boston, MA Q/A –	
5:15-6:45 pm	<b>Welcoming Reception</b>	<b>Fenway Room</b>
7:00 pm	<b>Poster Viewing</b>	<b>Maverick A&amp;B</b>

**Saturday, September 22, 2012**

7:30-8:30 am	<b>Continental Breakfast</b>	<b>Pre-Assembly</b>
	<b>Session 1</b> <b>Clinical Manifestations of Cancer Cachexia</b> <i>(Chair: Aminah Jatoi, MD)</i>	<b>Belvidere</b>
8:30-9:00 am	<b>Classification of cancer cachexia</b> Kenneth Fearon, MD, MBBCh. Hons. Professor of Surgical Oncology University of Edinburgh United Kingdom Q/A -	
9:00-9:30 am	<b>Body composition and prognostication in cancer</b> Vickie Baracos, PhD Professor and Alberta Cancer Foundation Chair in Palliative Medicine Department of Oncology University of Alberta Edmonton Alberta, Canada Q/A –	

- 9:30-9:45 am **(Short Talk 1) Cancer Cachexia: fitting classifications into clinical practice**  
Maurizio Muscaritoli, MD  
Department of Clinical Medicine  
University La Sapienza  
Rome, Italy  
Q/A
- 9:45-10:00 am **(Short Talk 2) Anti-cachexia melanocortin peptide with oral activity**  
Kenneth A. Gruber, PhD  
Tensive Controls, Inc  
Columbia, Missouri  
Q/A –
- 10:00-10:30 am **Coffee Break** **Pre-Assembly**
- 10:30 – 11:00 am **Onset and progression of cancer cachexia, results from the Montreal longitudinal study** **Belvidere**  
Bruno Gagnon, MD  
Assistant Professor  
Department of Medicine and Oncology  
Faculty of Medicine, McGill University  
Montreal, Quebec, Canada  
Q/A -
- 11:00-11:30 am **Interactions between antineoplastic therapy and cachexia: a medical oncology perspective”** **Belvidere**  
Michael Sawyer, MD  
Associate Professor, Department of Medical Oncology  
University of Alberta  
Cross Cancer Institute  
Edmonton, Alberta, Canada  
Q/A-
- 11:30-11:45 am **(Short Talk 3) Physical functions and sexual dimorphism**  
Nathan Stephens, MD  
Surgical Research Fellow, Tissue Injury & Repair  
University of Edinburgh  
Edinburgh, United Kingdom  
Q/A
- 11:45-12:00 pm **(Short Talk 4) Progressive skeletal muscle wasting and long-term impairment of mitochondrial function following repeated cyclical administration of doxorubicin and dexamethasone**  
Thomas Jagoe, MD, PhD  
Assistant Professor  
Department of Oncology  
McGill University  
Montreal, Quebec, Canada

12:00 noon      **Lunch**      **Fenway Room**

## **Session 2**

### **Mechanisms of Muscle**

#### **Wasting in Cancer Cachexia (Part 1)**

*(Chair: Denis Guttridge, PhD)*

**Belvidere**

1:30-2:00 pm      **New insights into the molecular mechanisms of muscle wasting and cachexia**

Alfred Goldberg, MD

Professor

Department of Cell Biology

Harvard Medical School

Boston, MA

Q/A -

2:00-2:30 pm      **Mechanisms of muscle wasting in cancer**

Josep Argiles, PhD

Professor

University of Barcelona

Barcelona, Spain

Q/A-

2:30-3:00 pm      **A novel pathway in TGFbeta signaling that controls muscle cachexia**

Marco Sandri, MD

Assistant Professor

Department of Biomedical Science

University of Padova

Padova, Italy

Q/A-

3:00-5:00 pm      **Poster Session (Judging) + Free Time**

**Maverick A&B  
Adams A&B**

## **Session 3:**

### **Mechanisms of Muscle Wasting in Cancer Cachexia, Part II**

*(Chair: Marion Couch, MD, PhD)*

**Belvidere**

5:00-5:30 pm      **Cellular signaling in cancer cachexia**

Denis Guttridge, PhD

Professor

Department of Molecular Virology, Immunology and Medical Genetics

The Ohio State University

Columbus, Ohio

Q/A -

5:30-6:00 pm	<b>The role of triglyceride lipases in cancer cachexia</b> Gerald Hoelfer, MD Professor of Pathology Institute of Pathology Medical University of Graz Graz, Austria Q/A-	<b>Belvidere</b>
6:00-6:15 pm	<b>(Short Talk 1) – Stat3 in cancer cachexia</b> Teresa Zimmers, PhD Associate Professor Department of Cell Biology Thomas Jefferson University Philadelphia, Pennsylvania Q/A -	
6:15-6:30 pm	<b>(Short Talk 2) - PGC-1<math>\alpha</math> isoform (PGC-1<math>\alpha</math> 4) regulates skeletal muscle wasting during cancer-induced cachexia</b> James White, PhD Research Fellow Dana Farber Cancer Center Harvard Medical School Cambridge, MA Q/A -	
6:30-6:45 pm	<b>(Short Talk 3) – The translation inhibitor pateamine A Prevents cachexia-induced muscle wasting in mice</b> Eddine Gallouzi, PhD Associate Professor Department of Biochemistry Goodman Cancer Center, McGill University Montreal, Quebec, Canada Q/A -	
7:00 pm	<b>Banquet</b>	<b>Fenway Room</b>
9:00 pm	<b>Evening Reception/Poster Viewing</b>	<b>Maverick A&amp;B Adams A&amp;B</b>
<b><u>Sunday, September 23, 2012</u></b>		
7:30-8:30 am	<b>Breakfast</b>	<b>Fenway Room</b>
	<b>Session 4: Involvement of Non-Muscle Tissue in Cancer Cachexia (Chair: Ken Fearon, MD)</b>	<b>Belvidere</b>

8:30-9:00 am	<p><b>Cardiac muscle wasting and fibrosis in cancer</b>          Jochen Springer, PhD          Center for Cardiovascular Research          Charite Campus Mitte          Berlin, Germany          Q/A -</p>	<b>Belvidere</b>
9:00-9:30 am	<p><b>Chemotherapy-induced cardiotoxicity</b>          Thomas Force, MD          Professor          Clinical Director Jefferson Center for Translational Medicine          Thomas Jefferson University          Philadelphia, Pennsylvania          Q/A-</p>	
9:30-9:45 am	<p><b>Short Talk 1 – Cause of death in cancer cachexia – the impact of CV drugs</b>          Andrew J. Stewart Coats, PhD          Professor and CEO, Norwich Research Park          Norwich, UK          Q/A</p>	
9:45-10:00 am	<p><b>(Short Talk 2) – Ryanodine receptor 1 remodeling in cancer associated muscle dysfunction</b>          David Waning, PhD          Assistant Research Professor          Indiana University School of Medicine          Indianapolis, Indiana          Q/A</p>	
10:00-10:30 am	<b>Coffee Break</b>	<b>Pre-Assembly</b>
10:30-11:00 am	<p><b>Mechanisms of cardiac atrophy in cancer</b>          Monte Willis, MD          Associate Professor          McAllister Heart Institute          Department of Pathology and Laboratory Medicine          University of North Carolina          Chapel Hill, North Carolina          Q/A</p>	
11:00-11:30 am	<p><b>Neuroendocrine influences in cachexia</b>          Daniel Marks, MD          Associate Professor          Doernbecher Children's Hospital          Oregon Health and Sciences University          Portland, Oregon          Q/A -</p>	<b>Belvidere</b>

11:30-11:45 am	<p><b>(Short Talk 3) – NF-κB signaling proteins and transcription factors required for cancer-induced muscle wasting</b>  Susan Kandarian, PhD  Professor, Department of Health Sciences  Boston University  Boston, MA  Q/A</p>	<b>Belvidere</b>
12:00-1:30 pm	<b>Lunch</b>	<b>Fenway Room</b>
	<p><b>Session 5:</b>  <b>Therapeutic Targets and Clinical Trials in Cancer Cachexia</b>  <i>(Chair: Vickie Baracos, PhD)</i></p>	<b>Belvidere</b>
1:30-2:00 pm	<p>Targeting myostatin as a potential therapy for cancer cachexia  Ronenn Roubenoff, MD  Novartis/Tufts University  Boston, MA  Q/A -</p>	
2:00-2:15 pm	<p><b>(Short Talk 1) Targeting ghrelin system for the management of cachexia/anorexia syndrome</b>  Egidio Del Fabbro, MD  Associate Professor  Department of Internal Medicine  Virginia Commonwealth University  Richmond, Virginia  Q/A –</p>	
2:15-2:45 pm	<p><b>Choosing the right clinical endpoints for a cachexia trial</b>  Florian Strasser, MD, ABHPM  Associate Professor  Oncological Palliative Medicine  Cantonal Hospital  St. Gallen, Switzerland  Q/A –</p>	
2:45-3:00 pm	<p><b>(Short Talk 2) – Cancer cachexia: Evaluation of body composition using CT scans and identification of genetic markers</b>  Neil Johns, MBBS, BSC, MRCS  Specialty Registrar in General Surgery  Clinical Surgery School of Clinical Sciences  University of Edinburgh  Edinburgh, UK</p>	
3:00-3:30 pm	<b>Coffee Break</b>	<b>Pre-Assembly</b>

- 3:30-4:00 pm      **Treatment development for cancer cachexia: current status, statistical issues & avoidable errors**      **Belvidere**  
Stefan Anker, MD, PhD  
Professor of Cardiology and Cachexia Research  
Department of Cardiology  
Charite Campus Virchow-Klinikum  
Berlin, Germany  
Q/A –
- 4:00-4:30 pm      **The challenges of recruiting and retaining patients onto cancer cachexia trials**  
Aminah Jatoi, MD  
Professor  
Department of Oncology  
Mayo Clinic  
Rochester, Minnesota  
Q/A -
- 4:30-4:45 p.m.      **(Short Talk 3) – Molecular mechanisms underlying reduced knee extensor function and walking endurance in cancer Patients: diminished myosin-actin cross-bridge kinetics**  
Michael Toth, PhD  
Department of Medicine  
University of Vermont College of Medicine  
Burlington, Vermont  
Q/A –
- 4:45-5:30 pm      **Panel Discussion (led by)**  
Marion Couch, MD, PhD  
Professor and Director  
Head and Neck Research, Department of Otolaryngology  
University of Vermont  
Burlington, Vermont
- 5:30-5:40 pm      **Closing Remarks** (Denis Guttridge)